Condition
Mesolthelioma|Esophageal Cancer|Lung Cancer|Thoracic Sarcomas|Thymoma
Estimated Enrollment: 44
Age Group: 18 Years to 99 Years (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Primary Purpose: Treatment
Study ID Numbers: 110041|11-C-0041
Study First Received: December 10, 2010
Last Updated: April 19, 2017
Estimated Primary Completion Date: June 13, 2016
Primary Outcome Measures:
Tabulation of patient toxicities and their grades|Number of patients of the first 10 sarcoma, mesothelioma and esophageal CA patients respectively with cell line development greater than or equal to 3|Enumeration and description of immune responses|Number of patients of first 20 lung CA patients with cell line development greater than or equal to 5.
Sponsors and Collaborators:
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Website Link: https://ClinicalTrials.gov/show/NCT01258868
